Article

Jasmine Martin Discusses Oral Adherence

Author(s):

Jasmine Martin

Jasmine Martin, Director, West Region Medical Science Liaison Team, Takeda Oncology, discusses oral adherence.

Jasmine Martin, Director, West Region Medical Science Liaison Team, Takeda Oncology, discusses oral adherence.

“If patients aren’t taking their drugs, then how do we know that the outcomes will be [the same as] what the clinical trial [outcomes] were?” Martin asks.

Related Videos
Image of man with grey hair.
Image of woman with black hair.
Image of a smiling woman with brown hair.
Image of a woman with short brown hair, wearing glasses.
Image of man with brown hair.
Image of woman with blonde hair.
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Image of a man wearing a black button-up shirt.
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Related Content
Image of multiple myeloma cells.
December 21st 2024

Darzalex Regimen May Improve MRD Responses in Multiple Myeloma

Kristie L. Kahl
Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
FDA approves Ryoncil for children with GVHD.
December 18th 2024

Ryoncil Receives FDA Approval for Children With GVHD

Darlene Dobkowski, MA
This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Illustration of cells.
December 10th 2024

Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma

Kristi Rosa
Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition.
Illustration of cancer cells representing multiple myeloma.
December 9th 2024

Tecvayli Effective Maintenance Therapy in Newly Diagnosed Multiple Myeloma

Jason Broderick
Tecvayli alone or plus Revlimid has been found to be safe and may result in high MRD-negativity rates.